GE Healthcare boosts profits; FDA rejects Alimera's eye implant again;

@FierceMedDev:  buying implant outfit for $80M with eye on Europe. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Roche is closing down its 454 Life Sciences gene sequencing division. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: FierceMedicalDevices' 2013 Fierce 15. Special report | Follow @MichaelGFierce

> GE Healthcare ($GE) boosted its third-quarter profits despite flat sales. Story

> For the third time, the FDA has rejected Alimera Sciences ($ALIM) and pSivida's ($PSDV) Iluvien, a back-of-the-eye implant that delivers a drug to treat diabetic vision loss. Story

> U.S.-based National Instruments has signed a memorandum of understanding with The Healthcare Technology Innovation Center in India to develop new, affordable medical devices. Story

> Researchers from Columbia University Medical Center found in a study that a narrow spectrum of UV light was effective in killing bacteria such as MRSA and didn't harm human skin. Item

> A new study concludes that CT and MRI machines are overused for headaches, despite recommendations against the practice. Story

> General Electric is seeking a patent for an electromagnetic system that would be designed to detect medical instruments in use during surgery, spotting where they are within a patient during a procedure. Story

Biotech News

@FierceBiotech: VC funding follows tepid pace in Q3 as first-time rounds shrivel. Special report | Follow @FierceBiotech

@JohnCFierce: Seamus Fernandez is downgrading Sanofi. Likes PCSK9 but thinks prospects are overblown. Lotso competition coming. Very sensible assessment. | Follow @JohnCFierce

@DamianFierce: The third time is not whatsoever charming as Alimera, pSivida get another FDA rejection for Iluvien. Article | Follow @DamianFierce

@EmilyMFierce: Mini pancreas grown in lab using mouse cells. Story from FierceBiotech Research | Follow @EmilyMFierce

> Boehringer snags EU nods for COPD drug as FDA awaits. More

> Bullish Relypsa eyes $138M in bumped-up IPO pitch. Story

> Blood clots force Ariad to shutter PhIII Iclusig trial. Article

Pharma News

@FiercePharma: Biggest story this a.m. online: Pharma dealmakers, listen up; Ireland may close a popular tax loophole. Story | Follow @FiercePharma

@EricPFierce: Another gut check for Amarin and its fish oil drug . F panel votes against wider use. Article | Follow @EricPFierce

@CarlyHFierce: Q3 earnings: Abbott ups dividend, Actelion confirms growth, Baxter hurt by merger costs. More | Follow @CarlyHFierce

> Valeant ordered to pay Anacor $100M. Story

> EP Vantage: Eliquis projected sales off 60% for 2014. Article

> NICE panel likes Astellas' Xtandi. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.